According to scientists at The Wistar Institute, the ADAR1p110 isoform regulates genome stability at telomeres and is required for continued proliferation of cancer cells. This finding, reported today in Nature Communications, reveals an additional oncogenic function of ADAR1 and reaffirms its potential as a therapeutic target in cancer.
There are two forms of the ADAR1 protein, ADAR1p150 and ADAR1p110. While the RNA editing role of the former has been extensively characterized, the function of the nuclear ADAR1p110 isoform had remained elusive.
"We discovered that in the nucleus, ADAR1p110 oversees a similar mechanism to ADAR1p150, the better-known cytoplasmic variant, but the editing process in this case targets particular nucleic acid structures called R-loops when formed at the chromosome ends," said Kazuko Nishikura, senior author of the study. "Through this function, ADAR1p110 seems to be essential for cancer cell proliferation."
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
R-loops form during gene transcription when, instead of dissociating from its template DNA strand, the newly synthesized RNA remains attached to it, leading to a stable DNA/RNA hybrid. While these structures can be beneficial for transcriptional regulation in certain conditions, accumulation of R-loops can cause DNA damage, chromosome rearrangements and genomic instability and is linked to neurological disorders and cancer.
Nishikura and colleagues found that ADAR1p110 helps the cells resolve R-loops and prevent their accumulation by editing both the DNA and the RNA strands involved in the structure and facilitating degradation of the RNA strand by the RNase H2 enzyme. Notably, the team found that ADAR1p110 depletion results in accumulation of R-loops at the chromosome ends, indicating that ADAR1p110 acts on R-loops formed in the telomeric regions and is required to preserve telomere stability.
"It has recently been suggested ADAR1 inhibitors could potentiate tumor response to immunotherapy by interfering with certain cytoplasmic ADAR1p150 functions," said Nishikura. "Based on our findings on the role of nuclear ADAR1p110 in maintaining telomere stability in cancer cells, we predict that ADAR1 inhibitors would be very effective anticancer therapeutics by interfering with two different and independent pro-oncogenic ADAR1functions exerted by the two isoforms."